Vera Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
atacicept (VT-001) / Vera Therap
2022-000257-83: A large global research study for an investigational drug called atacicept is being tested for the treatment of active lupus nephritis in a randomized manner, and is a placebo-controlled, double-blind study. Placebo-controlled provides a way to measure the actual effect of the investigational drug (atacicept). Double-blind means that the patient and the study doctor will not know if the patient is getting atacicept or placebo.

Not yet recruiting
3
290
Europe
Atacicept, VT-001, Solution for injection in pre-filled syringe
Vera Therapeutics, Inc., Vera Therapeutics, Inc.
patients with lupus nephritis sujetos con nefritis lúpica, Lupus nephritis is kidney inflammation caused by systemic lupus erythematosus (SLE). SLE is an autoimmune disease; a disorder in which the body's immune system attacks the body's own cells and organs., Body processes [G] - Immune system processes [G12]
 
 
ORIGIN, NCT04716231 / 2020-004892-41: Atacicept in Subjects With IgA Nephropathy

Active, not recruiting
3
376
US
Atacicept, VT-001, Placebo to match Atacicept
Vera Therapeutics, Inc.
IgA Nephropathy, Berger Disease
05/25
07/28
COMPASS, NCT05609812 / 2022-000257-83: Atacicept in Subjects With Active Lupus Nephritis

Withdrawn
3
360
Europe, US
Atacicept, VT-001, Placebo
Vera Therapeutics, Inc., Vera Therapeutics, Inc.
Lupus Nephritis (LN)
03/26
12/28
ORIGIN EXTEND, NCT06674577: A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

Enrolling by invitation
2
476
US
Atacicept 150 mg
Vera Therapeutics, Inc.
IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease
05/28
05/28
NCT06983028: Atacicept in Multiple Glomerular Diseases

Not yet recruiting
2
200
NA
Atacicept
Vera Therapeutics, Inc.
pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
11/27
11/27
NCT07020923: Monthly Dosing of Atacicept in IgAN

Recruiting
2
90
US
Atacicept, VT-001
Vera Therapeutics, Inc.
IgA Nephropathy (IgAN), Berger Disease
09/26
09/27
MAU868 / Vera Therap
No trials found
synthetic peptide nucleic acid oligomer therapeutic / Vera Therap
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
atacicept (VT-001) / Vera Therap
2022-000257-83: A large global research study for an investigational drug called atacicept is being tested for the treatment of active lupus nephritis in a randomized manner, and is a placebo-controlled, double-blind study. Placebo-controlled provides a way to measure the actual effect of the investigational drug (atacicept). Double-blind means that the patient and the study doctor will not know if the patient is getting atacicept or placebo.

Not yet recruiting
3
290
Europe
Atacicept, VT-001, Solution for injection in pre-filled syringe
Vera Therapeutics, Inc., Vera Therapeutics, Inc.
patients with lupus nephritis sujetos con nefritis lúpica, Lupus nephritis is kidney inflammation caused by systemic lupus erythematosus (SLE). SLE is an autoimmune disease; a disorder in which the body's immune system attacks the body's own cells and organs., Body processes [G] - Immune system processes [G12]
 
 
ORIGIN, NCT04716231 / 2020-004892-41: Atacicept in Subjects With IgA Nephropathy

Active, not recruiting
3
376
US
Atacicept, VT-001, Placebo to match Atacicept
Vera Therapeutics, Inc.
IgA Nephropathy, Berger Disease
05/25
07/28
COMPASS, NCT05609812 / 2022-000257-83: Atacicept in Subjects With Active Lupus Nephritis

Withdrawn
3
360
Europe, US
Atacicept, VT-001, Placebo
Vera Therapeutics, Inc., Vera Therapeutics, Inc.
Lupus Nephritis (LN)
03/26
12/28
ORIGIN EXTEND, NCT06674577: A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

Enrolling by invitation
2
476
US
Atacicept 150 mg
Vera Therapeutics, Inc.
IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease
05/28
05/28
NCT06983028: Atacicept in Multiple Glomerular Diseases

Not yet recruiting
2
200
NA
Atacicept
Vera Therapeutics, Inc.
pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
11/27
11/27
NCT07020923: Monthly Dosing of Atacicept in IgAN

Recruiting
2
90
US
Atacicept, VT-001
Vera Therapeutics, Inc.
IgA Nephropathy (IgAN), Berger Disease
09/26
09/27
MAU868 / Vera Therap
No trials found
synthetic peptide nucleic acid oligomer therapeutic / Vera Therap
No trials found

Download Options